文献速递前列腺癌

Decipher检测预测高危非转移性前列腺癌术后10年远处转移复发的验证

Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
PubMed 文献 · Eur Urol Oncol · 2019-01-11

本研究在高危非转移性前列腺癌术后患者中验证Decipher基因组分类器对10年内远处转移的预测作用,采用欧洲与美国两个病例对照队列,欧洲队列54例、美国验证队列298例。两队列中发生转移者Decipher评分中位数更高,多因素分析中Decipher评分每增加10%与10年内远处转移风险升高相关,欧洲队列OR 1.53(95%CI 1.06-2.22;p=0.025),美国队列OR 1.58(95%CI 1.31-1.92;p<0.001)。作者结论认为Decipher可预测高危非转移性前列腺癌术后转移复发。

要点

  • 两队列中发生远处转移者Decipher评分中位数均更高。
  • 欧洲队列Decipher评分每增10%的远处转移OR为1.53(95%CI 1.06-2.22;p=0.025)。
  • 美国队列Decipher评分每增10%的远处转移OR为1.58(95%CI 1.31-1.92;p<0.001)。

核心结论

  • 本研究验证Decipher可作为高危非转移性前列腺癌患者术后10年随访内转移复发的预测指标。

研究设计与样本

  • 欧洲三级转诊中心1991至2011年高危非转移性前列腺癌术后发生远处转移的患者与未发生远处转移的患者匹配(n=54)。
  • 采用类似美国病例对照队列进行验证研究(n=298)。
  • 使用原发前列腺癌病灶的福尔马林固定石蜡包埋组织块进行RNA提取与基因表达分析。

主要发现

  • 欧洲与美国病例对照研究中,发生转移人群的Decipher评分中位数均更高。
  • 多因素分析中,Decipher评分每增加10%,欧洲队列10年内远处转移风险OR为1.53(95%CI 1.06-2.22;p=0.025)。
  • 多因素分析中,Decipher评分每增加10%,美国队列10年内远处转移风险OR为1.58(95%CI 1.31-1.92;p<0.001)。
  • 欧洲队列中位随访时间为12年(四分位距8-12)。

局限性

  • 研究局限性为欧洲队列样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decipher is a genomic classifier designed to predict the development of distant metastases after surgical treatment of prostate cancer (PC). Its long-term prognostic role in a high-risk PC population has not been investigated previously. OBJECTIVE: To determine the prognostic role of the Decipher genomic classifier in two high-risk PC case-control studies. DESIGN, SETTING, AND PARTICIPANTS: Patients who developed distant metastases after surgery for high-risk, nonmetastatic PC in a European tertiary referral center from 1991 to 2011 were matched to patients not developing distant metastases (n=54). A validation study (n=298) was performed using a similar US case-control cohort. Formalin-fixed, paraffin-embedded tissue blocks from the index PC lesion were used for RNA extraction and gene expression analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome investigated was the development of distant metastasis within 10-yr follow-up. Multivariable logistic regression analysis was performed, with statistical significance considered at p<0.05. RESULTS AND LIMITATIONS: In both the European and US case-control studies, the median Decipher scores were higher in the population that developed metastases. In the multivariable analysis, each 10% increase in Decipher score translated to an increase in the risk of distant metastases within 10-yr follow-up, with an odds ratio of 1.53 (95% confidence interval [CI] 1.06-2.22; p=0.025) and 1.58 (95% CI 1.31-1.92; p<0.001) for the European and US cohorts, respectively. Median follow-up for the European cohort was 12yr (interquartile range 8-12). The study limitation is the small size of the European cohort. CONCLUSIONS: Our study validates Decipher as a predictor for metastatic recurrence even in patients with high-risk, nonmetastatic PC within 10-yr follow-up. PATIENT SUMMARY: Decipher is a test based on gene expression profiles in primary tumors in prostate cancer. It has already been proven to predict cancer recurrence after surgery, but this has not yet been shown for patients with high-risk prostate cancer. This is the first study confirming that Decipher predicts a patient's risk of developing cancer recurrence after surgery for high-risk prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Van den Broeck T, Moris L, Gevaert T, et al. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Eur Urol Oncol. 2019. PMID: 31411980. doi:10.1016/j.euo.2018.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。